rCBF was normal in 4 patients (3 with predominantly positive symptoms and 1 with predominantly negative symptoms) . Figure 1 Baseline single photon emission computed tomography (SPECT) shows reduced perfusion in the left parietal and temporal cortices in 11 out of 14 patients with predominantly

positive symptoms. Figure 2 Baseline single photon emission computed tomography (SPECT) shows reduced perfusion in the right ventromedial frontal cortex in 11 out of 14 patients with predominantly positive symptoms. Figure 3 Baseline single photon emission computed tomography (SPECT) shows reduced perfusion in the frontal cortex and the left orbitofrontal Inhibitors,research,lifescience,medical cortex and decreased regional cerebral blood flow (rCBF) in the right basal ganglia, in 6 out of 7 patients with predominantly … The cortical

abnormalities observed in patients at baseline persisted after treatment. After treatment, additional changes in SB203580 molecular weight subcortical structures were also observed, Inhibitors,research,lifescience,medical notably an increase in rCBF in the left screening libraries caudate nuclei in 14 patients (Figure Inhibitors,research,lifescience,medical 4)3 Figure 4 Single photon emission computed tomography (SPECT) after treatment in 1 4 patients showed an increase in regional cerebral blood flow (rCBF) in the left caudate nuclei. Discussion These results are consistent with the finding of Liddle et al on rCBF patterns Inhibitors,research,lifescience,medical in schizophrenia,4,5 who reported both increases and decreases in rCBF, suggesting a dynamic imbalance rather than a fixed abnormality Conclusion Our data suggest cortical abnormalities in rCBF, at baseline and after treatment, conceivably correlated with the type of symptoms. Subcortical changes

appearing during treatment (notably Inhibitors,research,lifescience,medical in the left caudate nuclei) may be the consequence of treatment, but not of any one specific drug in particular.
A decade ago, the schizophrenia prevention movement was launched with great expectations. At that time, a handful of treatment studies began, founded more on enthusiasm, Intuition, and Indirect findings than on a solid base of evidence. Today, though still In Its Infancy, the field thrives. Early Intervention programs have dramatically proliferated around the world, and the data, though still sparse, are nonetheless quite encouraging. The target of these studies Is the schizophrenia “prodrome,” which refers AV-951 to the phase of illness that precedes the onset of psychosis. Treatment, to date, has been largely pharmacological, although at least one major psychotherapy trial has now begun in the United Kingdom.1 In this paper, we will review the treatment findings currently available that address the following basic issues: (i) what should be treated; (ii) when should treatment be initiated; and (iii) how long should treatment last.